With a focus on life science, the group has achieved strong growth, reaching SEK 1,807 million in 2024 revenue and a 23% EBITA CAGR over five years. Its buy & build strategy targets scalable, profitable companies in non-cyclical, demographically driven markets.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.